Although existing CRISPR-Cas-based imaging methods can target endogenous genomic sequences, their applications are limited by system complexity and sensitivity, particularly when imaging ...

Despite the price target reduction, Baird indicated there was "no change to outlook on earnings" in its assessment of CRISPR Therapeutics. In other recent news, CRISPR Therapeutics reported its ...

Clear Street lowered the firm’s price target on Crispr Therapeutics (CRSP) to $50 from $52 and keeps a Hold rating on the shares. Crispr is trading even after reporting Q3 results, which showed a ...

Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some ...

In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn LDL cholesterol and triglycerides in patients whose levels refused to budge ...

Investing.com - RBC Capital has raised its price target on CRISPR Therapeutics (NASDAQ:CRSP) to $50.00 from $42.00 while maintaining a Sector Perform rating. The stock currently trades at $54.58, ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up roughly 3.8% of ARK Investment’s disclosed equity portfolio at ...

A recent review published in Genes & Diseases by researchers from the Naval Medical University and the 922nd Hospital of the Joint Service Support Force of the PLA provides a comprehensive overview of ...

Learn more about whether Aurinia Pharmaceuticals Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.